51
|
Aversa C, Rossi V, Geuna E, Martinello R, Milani A, Redana S, Valabrega G, Aglietta M, Montemurro F. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014; 23:623-8. [PMID: 24993072 DOI: 10.1016/j.breast.2014.06.009] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2014] [Revised: 05/16/2014] [Accepted: 06/08/2014] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Breast cancer (BC) subtypes have different survival and response to therapy. We studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype. PATIENTS AND METHODS 488 patients with diagnosis of metastatic BC were retrospectively evaluated. According to the combination of hormone receptors (HR) and HER2 status, tumors were grouped in: Luminal (Lum), Luminal/HER2+, pure HER2-positive (pHER2+) and triple negative (TN). Time to CNS progression, CNS-M free interval and Overall Survival (OS) after CNS-M occurrence were compared by the log-rank test. Cox-proportional hazard models were used to study predictor factors associated with CNS progression, including tumor subtype and all potentially clinical relevant variables. RESULTS 115 patients (pts) developed CNS-M with a median time to CNS progression of 31 months. The rate of CNS-M by subtype was: Lum 14%, Lum/HER2+ 35%, pHER2+ 49%, TN 22% (p < 0.001). Compared with Lum tumors, Lum/HER2+ (HR 2.514, p < 0.001), pHER2+ (HR 6.799, p < 0.0001) and TN (HR = 3.179, p < 0.001) subtypes were at higher risk of CNS-M. Median OS in months after CNS-M was: Lum 7.4, Lum/HER2+ 19.2, pHER2+ 7, TN 4.9 (p < 0.002). Belonging to the Lum/HER2+ subtype (HR 0.48, p < 0.037) and having isolated CNS (HR 0.37, p < 0.004) predicted significantly reduced risk of death. CONCLUSIONS After CNS-M, the Lum/HER2+ subtype appears associated with the longest OS. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic CNS lesions and of more aggressive CNS-M treatment in Lum/HER2+ subtype.
Collapse
Affiliation(s)
- C Aversa
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy
| | - V Rossi
- Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy.
| | - E Geuna
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy
| | - R Martinello
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy
| | - A Milani
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy
| | - S Redana
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy
| | - G Valabrega
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy
| | - M Aglietta
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy
| | - F Montemurro
- Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy; Department of Oncology, University of Torino Medical School, Italy; Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia (FPO)-Candiolo Cancer Center (IRCCs), Turin, Italy
| |
Collapse
|
52
|
Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galvan P, Sapino A, Aglietta M, Baselga J, Scaltriti M. Abstract P1-08-23: Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p1-08-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: In 2009 we started a prospective, randomized Phase II trial to evaluate HER2-targeting without chemotherapy (CT) in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts). Although the study was prematurely closed because of slow accrual, we decided to analyze the primary tumors in order to identify possible biomarkers that could identify, among the enrolled pts, those deriving the longest lasting benefit from HER2-targeting without CT.
Experimental Design: In the HERLAP study (NCT00842998), pts with HER2+ MBC were randomized to trastuzumab or lapatinib as first-line therapy. Patients showing radiological signs of tumor regression after 8 weeks of treatment were allowed to continue on single agent anti-HER2 therapy until disease progression. CT was added to anti-HER-2 therapy in pts failing to achieve tumor regression at the 8-week evaluation and in those progressing at any time. Expression analysis of 105 selected genes was performed from formalin-fixed paraffin-embedded primary tumor samples. The research-based PAM50 intrinsic subtypes (Luminal A, Luminal B, HER2-enriched and Basal-like) and the normal breast-like group were also identified. Additionally, quantitative HER2 (H2T) and p95HER2 (p95) protein expression were evaluated using the HERmark® assay and the p95 VeraTag® assay, respectively. Potential predictors of persistence on protocol (PP, time from randomization to addition of chemotherapy to anti HER2-therapy or death from any cause) were studied by univariate and multivariate analysis.
Results: Nineteen patients were enrolled. Median overall survival was 43 months and median PP was 3.8 months (0.8-38.8+) with 4 pts (21.1%) persisting on single agent T or L for longer than 12 months (14.9-38.8+ months). Seventeen pts were evaluable for PP. Gene expression analysis revealed that high expression of the 17q12-21 amplicon genes HER2 and GRB7, and the PAM50 HER2-enriched intrinsic profile, were significantly associated with longer PP. Conversely, high expression of luminal-related genes such as PGR, MDM2 and PIK3CA, or the PAM50 luminal intrinsic profile, were found associated with reduced PP. Quantitative H2T and p95 expression revealed that, increasing H2T/p95 ratio significantly associated with longer PP (HR 0.969, p = 0.010).
When analyzed as a multivariable model, PAM50 intrinsic subtype and H2T/p95 ratio dichotomized around the median value independently predicted for longer PP (PAM50 non-luminal vs. Luminal A+B, HR 0.164, p = 0.078 and H2T/p95 ratio higher vs. lower/equal, HR 0.294, p = 0.062 respectively).
Conclusions: Our data suggest that tumors belonging to the PAM50 “HER2-enriched” subtype tumors and/or with high H2T/p95 protein expression ratio are exquisitely sensitive to anti HER2-agents. MBC pts with these tumors may be candidates for studies aimed at establishing chemotherapy-free approaches.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-23.
Collapse
Affiliation(s)
- F Montemurro
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - A Prat
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - V Rossi
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - G Valabrega
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - J Sperinde
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - C Peraldo-Neia
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - M Donadio
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - P Galvan
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - A Sapino
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - M Aglietta
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - J Baselga
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| | - M Scaltriti
- Fondazione del Piemonte per l'Oncologia/IRCCCandiolo; Vall d'Hebron Institute of Oncology (VHIO); Monogram Biosciences; A.O. Città della Salute e della Scienza di Torino; Università di Torino; Memorial Sloan Kettering Cancer Center
| |
Collapse
|
53
|
Ascierto PA, Simeone E, Sileni VC, Queirolo P, Del Vecchio M, Di Guardo L, Guidoboni M, Marchetti P, Cappellini GCA, Ferrucci PF, Cognetti F, Bernengo MG, Guida M, Marconcini R, Mandalà M, Cimminiello C, Rinaldi G, Aglietta M, Calabrò L, Maio M. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP). J Immunother Cancer 2013. [PMCID: PMC3990978 DOI: 10.1186/2051-1426-1-s1-p69] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
54
|
Montemurro F, Gatti M, Redana S, Jacomuzzi ME, Nanni D, Durando A, Popolo M, Ponzone R, Rossi A, Albieri V, Valabrega G, Sismondi P, Gabriele P, Aglietta M. Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer. J Chemother 2013; 18:90-7. [PMID: 16572899 DOI: 10.1179/joc.2006.18.1.90] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
We evaluated whether concurrent radiotherapy (RT) affected delivery and toxicity of adjuvant intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in women with operable breast cancer. The medical charts of 321 consecutive breast cancer patients who received CMF either alone for 6 cycles, or for 4 cycles following of an anthracycline (A-CMF) were reviewed. One hundred forty-four women underwent radiotherapy concurrently with CMF. Optimal CMF delivery (success as opposite to failure) was defined as the combined achievement of an average relative dose intensity (aRDI) > or = 85% and an average percent of the total dose (aPTD) > or = 90% for the three drugs in the CMF regimen. Multivariate logistic regression analysis showed that concurrent-RT did not affect CMF delivery (OR for success 1.391 p=0.230). The sequential A-CMF regimen (OR for success 0.208, 95% C.I. 0.120-0.360, p<0.001) and age > or = 56 (OR for success 0.351, 95% C.I. 0.200-0.161, p<0.001) were independently associated with suboptimal CMF delivery. Moreover, concurrent RT was independently associated with increased leukopenia, thrombocytopenia, upper abdominal pain, mucositis and fatigue. Our retrospective analysis suggests that concurrent-RT has no impact on optimal CMF delivery, but it increases the burden of CMF-related toxicity.
Collapse
Affiliation(s)
- F Montemurro
- Unit of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
55
|
Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 2013; 24:1740-1748. [PMID: 23585514 DOI: 10.1093/annonc/mdt133] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023] Open
Abstract
BACKGROUND The use of anti-HER2 monoclonal antibodies (mAbs) has improved the clinical outcome of HER2-overexpressing breast cancers (BCs). Unfortunately, often these tumors tend to relapse and, when metastatic, the duration of clinical benefit is limited over time and almost invariably followed by tumor progression. Alternative approaches to this essentially passive immunotherapy are therefore needed in HER2-overexpressing BC patients. As HER2 is one of the most suitable targets for active immunotherapy in BC, manipulating the immune system is a highly attractive approach. MATERIAL AND METHODS A computer-based literature search was carried out using PubMed (keywords: breast neoplasm, HER2 vaccine, immunology); data reported at international meetings were included. RESULTS This review provides a focus on the following active vaccinal approaches under clinical investigation against HER2-overexpressing BC: (i) peptide and protein based; (ii) DNA based; (iii) whole tumor cell based; (iv) dendritic cell based. Moreover, the review discuss future challenges in the field, trying to define the best setting for the development of this innovative strategy, considering both immunological and clinical aspects of HER2 targeting. CONCLUSIONS Development of effective vaccines for BC remains a distinct challenge but is likely to become a substantial advance for patients with HER2-overexpressing BCs.
Collapse
Affiliation(s)
- A Milani
- Medical Oncology I, Institute for Cancer Research and Treatment (IRCC) Candiolo FPO (Fondazione del Piemonte per l'Oncologia); Department of Oncology, University of Torino Medical School, Candiolo
| | - D Sangiolo
- Medical Oncology I, Institute for Cancer Research and Treatment (IRCC) Candiolo FPO (Fondazione del Piemonte per l'Oncologia); Department of Oncology, University of Torino Medical School, Candiolo
| | - F Montemurro
- Medical Oncology I, Institute for Cancer Research and Treatment (IRCC) Candiolo FPO (Fondazione del Piemonte per l'Oncologia); Investigative Clinical Oncology Unit (INCO), Candiolo, Italy
| | - M Aglietta
- Medical Oncology I, Institute for Cancer Research and Treatment (IRCC) Candiolo FPO (Fondazione del Piemonte per l'Oncologia); Department of Oncology, University of Torino Medical School, Candiolo
| | - G Valabrega
- Medical Oncology I, Institute for Cancer Research and Treatment (IRCC) Candiolo FPO (Fondazione del Piemonte per l'Oncologia); Department of Oncology, University of Torino Medical School, Candiolo.
| |
Collapse
|
56
|
Aglietta M, Castellina A, Maldera S, Morello C. Extension of the dynamic range of large photocathode PMTs for a UHECR detector. EPJ Web of Conferences 2013. [DOI: 10.1051/epjconf/20135308016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
57
|
Pignochino Y, Capozzi F, Dell'Aglio C, Basiricò M, D'ambrosio L, Galizia D, Palesandro E, Benassi M, Aglietta M, Grignani G. 350 Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitors Potentiate Trabectedin Activity in Preclinical Models of Bone and Soft Tissue Sarcomas. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72148-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
58
|
Leone F, Marino D, Artale S, Cagnazzo C, Cascinu S, Martoni A, Sobrero A, Tampellini M, Siena S, Aglietta M. Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33219-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
59
|
Agafonova NY, Aglietta M, Antonioli P, Ashikhmin VV, Bari G, Bertoni R, Bressan E, Bruno G, Dadykin VL, Fulgione W, Galeotti P, Garbini M, Ghia PL, Giusti P, Kemp E, Mal'gin AS, Miguez B, Molinario A, Persiani R, Pless IA, Ryasny VG, Ryazhskaya OG, Saavedra O, Sartorelli G, Shakyrianova IR, Selvi M, Trinchero GC, Vigorito C, Yakushev VF, Zichichi A, Razeto A. Measurement of the velocity of neutrinos from the CNGS beam with the large volume detector. Phys Rev Lett 2012; 109:070801. [PMID: 23006352 DOI: 10.1103/physrevlett.109.070801] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Indexed: 06/01/2023]
Abstract
We report the measurement of the time of flight of ∼17 GeV ν(μ) on the CNGS baseline (732 km) with the Large Volume Detector (LVD) at the Gran Sasso Laboratory. The CERN-SPS accelerator has been operated from May 10th to May 24th 2012, with a tightly bunched-beam structure to allow the velocity of neutrinos to be accurately measured on an event-by-event basis. LVD has detected 48 neutrino events, associated with the beam, with a high absolute time accuracy. These events allow us to establish the following limit on the difference between the neutrino speed and the light velocity: -3.8 × 10(-6) < (v(ν)-c)/c < 3.1 × 10(-6) (at 99% C.L.). This value is an order of magnitude lower than previous direct measurements.
Collapse
Affiliation(s)
- N Yu Agafonova
- Institute for Nuclear Research, Russian Academy of Sciences, Moscow, Russia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
60
|
Abreu P, Aglietta M, Ahn EJ, Albuquerque IFM, Allard D, Allekotte I, Allen J, Allison P, Almeda A, Alvarez Castillo J, Alvarez-Muñiz J, Ambrosio M, Aminaei A, Anchordoqui L, Andringa S, Antičić T, Aramo C, Arganda E, Arqueros F, Asorey H, Assis P, Aublin J, Ave M, Avenier M, Avila G, Bäcker T, Balzer M, Barber KB, Barbosa AF, Bardenet R, Barroso SLC, Baughman B, Bäuml J, Beatty JJ, Becker BR, Becker KH, Bellétoile A, Bellido JA, Benzvi S, Berat C, Bertou X, Biermann PL, Billoir P, Blanco F, Blanco M, Bleve C, Blümer H, Boháčová M, Boncioli D, Bonifazi C, Bonino R, Borodai N, Brack J, Brogueira P, Brown WC, Bruijn R, Buchholz P, Bueno A, Burton RE, Caballero-Mora KS, Caramete L, Caruso R, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Cheng SH, Chiavassa A, Chinellato JA, Chirinos Diaz J, Chudoba J, Clay RW, Coluccia MR, Conceição R, Contreras F, Cook H, Cooper MJ, Coppens J, Cordier A, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Dallier R, Dasso S, Daumiller K, Dawson BR, de Almeida RM, De Domenico M, De Donato C, de Jong SJ, De La Vega G, de Mello Junior WJM, de Mello Neto JRT, De Mitri I, de Souza V, de Vries KD, Decerprit G, del Peral L, del Río M, Deligny O, Dembinski H, Dhital N, Di Giulio C, Díaz Castro ML, Diep PN, Dobrigkeit C, Docters W, D'Olivo JC, Dong PN, Dorofeev A, dos Anjos JC, Dova MT, D'Urso D, Dutan I, Ebr J, Engel R, Erdmann M, Escobar CO, Espadanal J, Etchegoyen A, Facal San Luis P, Fajardo Tapia I, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferguson AP, Ferrero A, Fick B, Filevich A, Filipčič A, Fliescher S, Fracchiolla CE, Fraenkel ED, Fröhlich U, Fuchs B, Gaior R, Gamarra RF, Gambetta S, García B, Garcia-Gamez D, Garcia-Pinto D, Gascon A, Gemmeke H, Gesterling K, Ghia PL, Giaccari U, Giller M, Glass H, Gold MS, Golup G, Gomez Albarracin F, Gómez Berisso M, Gonçalves P, Gonzalez D, Gonzalez JG, Gookin B, Góra D, Gorgi A, Gouffon P, Gozzini SR, Grashorn E, Grebe S, Griffith N, Grigat M, Grillo AF, Guardincerri Y, Guarino F, Guedes GP, Guzman A, Hague JD, Hansen P, Harari D, Harmsma S, Harrison TA, Harton JL, Haungs A, Hebbeker T, Heck D, Herve AE, Hojvat C, Hollon N, Holmes VC, Homola P, Hörandel JR, Horneffer A, Horvath P, Hrabovský M, Huege T, Insolia A, Ionita F, Italiano A, Jarne C, Jiraskova S, Josebachuili M, Kadija K, Kampert KH, Karhan P, Kasper P, Kégl B, Keilhauer B, Keivani A, Kelley JL, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapp J, Koang DH, Kotera K, Krohm N, Krömer O, Kruppke-Hansen D, Kuehn F, Kuempel D, Kulbartz JK, Kunka N, La Rosa G, Lachaud C, Lauer R, Lautridou P, Le Coz S, Leão MSAB, Lebrun D, Lebrun P, Leigui de Oliveira MA, Lemiere A, Letessier-Selvon A, Lhenry-Yvon I, Link K, López R, Lopez Agüera A, Louedec K, Lozano Bahilo J, Lu L, Lucero A, Ludwig M, Lyberis H, Macolino C, Maldera S, Mandat D, Mantsch P, Mariazzi AG, Marin J, Marin V, Maris IC, Marquez Falcon HR, Marsella G, Martello D, Martin L, Martinez H, Martínez Bravo O, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, Medina-Tanco G, Melissas M, Melo D, Menichetti E, Menshikov A, Mertsch P, Meurer C, Mićanović S, Micheletti MI, Miller W, Miramonti L, Molina-Bueno L, Mollerach S, Monasor M, Monnier Ragaigne D, Montanet F, Morales B, Morello C, Moreno E, Moreno JC, Morris C, Mostafá M, Moura CA, Mueller S, Muller MA, Müller G, Münchmeyer M, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Nelles A, Neuser J, Nhung PT, Niemietz L, Nierstenhoefer N, Nitz D, Nosek D, Nožka L, Nyklicek M, Oehlschläger J, Olinto A, Olmos-Gilbaja VM, Ortiz M, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Palmieri N, Parente G, Parizot E, Parra A, Parsons RD, Pastor S, Paul T, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Pesce R, Petermann E, Petrera S, Petrinca P, Petrolini A, Petrov Y, Petrovic J, Pfendner C, Phan N, Piegaia R, Pierog T, Pieroni P, Pimenta M, Pirronello V, Platino M, Ponce VH, Pontz M, Privitera P, Prouza M, Quel EJ, Querchfeld S, Rautenberg J, Ravel O, Ravignani D, Revenu B, Ridky J, Riggi S, Risse M, Ristori P, Rivera H, Rizi V, Roberts J, Robledo C, Rodrigues de Carvalho W, Rodriguez G, Rodriguez Martino J, Rodriguez Rojo J, Rodriguez-Cabo I, Rodríguez-Frías MD, Ros G, Rosado J, Rossler T, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Rühle C, Salamida F, Salazar H, Salesa Greus F, Salina G, Sánchez F, Santo CE, Santos E, Santos EM, Sarazin F, Sarkar B, Sarkar S, Sato R, Scharf N, Scherini V, Schieler H, Schiffer P, Schmidt A, Scholten O, Schoorlemmer H, Schovancova J, Schovánek P, Schröder F, Schulte S, Schuster D, Sciutto SJ, Scuderi M, Segreto A, Settimo M, Shadkam A, Shellard RC, Sidelnik I, Sigl G, Silva Lopez HH, Smiałkowski A, Smída R, Snow GR, Sommers P, Sorokin J, Spinka H, Squartini R, Stanic S, Stapleton J, Stasielak J, Stephan M, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Suša T, Sutherland MS, Swain J, Szadkowski Z, Szuba M, Tamashiro A, Tapia A, Tartare M, Taşcău O, Tavera Ruiz CG, Tcaciuc R, Tegolo D, Thao NT, Thomas D, Tiffenberg J, Timmermans C, Tiwari DK, Tkaczyk W, Todero Peixoto CJ, Tomé B, Tonachini A, Travnicek P, Tridapalli DB, Tristram G, Trovato E, Tueros M, Ulrich R, Unger M, Urban M, Valdés Galicia JF, Valiño I, Valore L, van den Berg AM, Varela E, Vargas Cárdenas B, Vázquez JR, Vázquez RA, Veberič D, Verzi V, Vicha J, Videla M, Villaseñor L, Wahlberg H, Wahrlich P, Wainberg O, Walz D, Warner D, Watson AA, Weber M, Weidenhaupt K, Weindl A, Westerhoff S, Whelan BJ, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Will M, Williams C, Winchen T, Winnick MG, Wommer M, Wundheiler B, Yamamoto T, Yapici T, Younk P, Yuan G, Yushkov A, Zamorano B, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Zhu Y, Zimbres Silva M, Ziolkowski M. Measurement of the proton-air cross section at √s=57 TeV with the Pierre Auger Observatory. Phys Rev Lett 2012; 109:062002. [PMID: 23006259 DOI: 10.1103/physrevlett.109.062002] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2011] [Indexed: 06/01/2023]
Abstract
We report a measurement of the proton-air cross section for particle production at the center-of-mass energy per nucleon of 57 TeV. This is derived from the distribution of the depths of shower maxima observed with the Pierre Auger Observatory: systematic uncertainties are studied in detail. Analyzing the tail of the distribution of the shower maxima, a proton-air cross section of [505±22(stat)(-36)(+28)(syst)] mb is found.
Collapse
Affiliation(s)
- P Abreu
- LIP and Instituto Superior Técnico, Technical University of Lisbon, Lisbon, Portugal
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
61
|
Martino M, Ballestrero A, Zambelli A, Secondino S, Aieta M, Bengala C, Liberati AM, Zamagni C, Musso M, Aglietta M, Schiavo R, Castagna L, Rosti G, Bruno B, Pedrazzoli P. Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplant 2012; 48:414-8. [PMID: 22863724 DOI: 10.1038/bmt.2012.149] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The median survival of women with metastatic breast cancer (MBC) is 18-24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous hematopoietic SCT (AHSCT) in Italy between 1990 and 2005. Data set for survival analysis has been obtained for 415 patients. Clinical parameters including probability of transplant-related mortality (TRM), PFS and OS. With a median follow-up of 27 months (range 0-172), OS and PFS at 5 and 10 years in the whole population were 47/23 and 32/14%, respectively. A total 239 patients are alive with a median follow-up of 33 months (range 2-174). Survival was significantly more pronounced in patients harboring hormone receptor positive tumors (P=0.028), without visceral metastases (P=0.009) and in women with chemosensitive disease (P<0.0001). Sixty eight patients (20.4%) who received HDC in partial response, stable or progressive disease underwent conversion to CR. TRM was 2.5% overall and 1.3% since 2000. Our findings suggest that could be a role for HDC and AHSCT in delaying disease progression and possibly cure a subset of MBC patient harboring chemosensitive tumors.
Collapse
Affiliation(s)
- M Martino
- Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera BMM, Reggio Calabria, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
62
|
Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, Silvestris N, Berardi R, Masini C, Calipari N, Ottaviani D, Catalano V, Badalamenti G, Giannicola R, Fabbri F, Venditti O, Fratto ME, Mazzara C, Latiano TP, Bertolini F, Petrelli F, Ottone A, Caroti C, Salvatore L, Falcone A, Giordani P, Addeo R, Aglietta M, Cascinu S, Barni S, Maiello E, Tonini G. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol 2012; 23:2072-2077. [PMID: 22219016 DOI: 10.1093/annonc/mdr572] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. PATIENTS AND METHODS This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. RESULTS Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P=0.009) and produced a trend toward improved overall survival versus no zoledronic acid. CONCLUSION This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.
Collapse
Affiliation(s)
- D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome.
| | - M Tampellini
- Department of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano, Torino
| | - B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - T Ibrahim
- Osteo-oncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì-Cesena
| | - C Ortega
- Oncological Department, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino
| | - V Virzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - N Silvestris
- Medical and Experimental Oncology Unit, Oncology Institute Giovanni Paolo II, Bari
| | - R Berardi
- Department of Medical Oncology, Universita Politecnica delle Marche, Ancona
| | - C Masini
- Department of Medical Oncology, University Hospital, Modena
| | - N Calipari
- Department of Radiotherapy, Ospedali Riuniti, Reggio Calabria
| | - D Ottaviani
- Department of Medical Oncology, Presidio Sanitario Gradenigo, Turin
| | - V Catalano
- Department of Medical Oncology, A.O. Ospedali Riuniti Marche Nord, Pesaro
| | - G Badalamenti
- Department of Surgery and Oncology, Policlinico Universitario 'P. Giaccone', Palermo
| | - R Giannicola
- Department of Medical Oncology, Ospedali Riuniti, Reggio Calabria
| | - F Fabbri
- Osteo-oncology Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forlì-Cesena
| | - O Venditti
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - M E Fratto
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - C Mazzara
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - T P Latiano
- Department of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
| | - F Bertolini
- Department of Medical Oncology, University Hospital, Modena
| | - F Petrelli
- Department of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Bergamo
| | - A Ottone
- Department of Medical Oncology, University of Torino, San Luigi Hospital, Orbassano, Torino
| | - C Caroti
- S.C. Medical Oncology, Galliera Hospital, Genoa
| | - L Salvatore
- Division of Medical Oncology, Department of Oncology, University Hospital S. Chiara, Pisa
| | - A Falcone
- Division of Medical Oncology, Department of Oncology, University Hospital S. Chiara, Pisa
| | - P Giordani
- Department of Medical Oncology, A.O. Ospedali Riuniti Marche Nord, Pesaro
| | - R Addeo
- Department of Medical Oncology, Ospedale San Giovanni di Dio di Frattamaggiore, Naples
| | - M Aglietta
- Oncological Department, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino; Department of Clinical Oncology, University of Torino Medical School - Institute for Cancer Research and Treatment, Candiolo, Torino, Italy
| | - S Cascinu
- Department of Medical Oncology, Universita Politecnica delle Marche, Ancona
| | - S Barni
- Department of Medical Oncology, Azienda Ospedaliera Treviglio-Caravaggio, Treviglio, Bergamo
| | - E Maiello
- Department of Onco-Hematology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| |
Collapse
|
63
|
Berger M, Grignani G, Giostra A, Ferrari S, Ferraresi V, Tamburini A, Cefalo G, Carnevale-Schianca F, Vassallo E, Picci P, Pagano M, Aglietta M, Pellerito R, Fagioli F. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol 2012; 23:1899-905. [DOI: 10.1093/annonc/mdr542] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
64
|
Montemurro F, Maggiorotto F, Valabrega G, Kubatzki F, Rossi V, Marocco F, Magistris A, Gatti M, Sarotto I, Aglietta M, Ponzone R. P3-07-04: Does Omission of Axillary Dissection after a Positive Sentinel Node Biopsy Influence Indication to Adjuvant Chemotherapy in Operable Breast Cancer Patients? Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-07-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Based on the recently published ACSOG Z0011 study (JAMA 2011;305:569), axillary dissection (AD) may be avoided in breast cancer (BC) patients with a clinically negative axilla and a positive sentinel lymph node (SLN) biopsy receiving breast conserving surgery (BCS). Because the number of positive axillary lymph nodes (ALN) is a widely accepted prognostic marker, we evaluated the potential impact of omission of AD on indication to adjuvant chemotherapy (ACT).
Patients and methods: Among 1497 patients operated at our Institution over 10 years, we identified 321 patients fulfilling the inclusion criteria of the ACSOG Z0011 study (BCS plus SLNB, cT1-2, cN0 breast cancer and 1 to 2 positive SLN). All patients underwent AD. Each case, which was anonymized, was reviewed by our breast team in two rounds. In the first round, patient age, histopathology, linfovascular invasion, tumor grade, hormone receptor, HER2, and ki67 status and number of positive SN nodes (micro and/or macrometastatic) were available. In the second round, the information on ALN was added. At each round, the panel chose between three indications: 1) Recommend ACT; 2) Discuss ACT; 3) No ACT. Results: SN was micrometastatic in 145 (45%) and macrometastatic in 176 patients (55%). ALD revealed non-SNs metastases in 96 patients (30%). Forty-four of these patients had >3 positive ALN (range 4–24). Indications at round 1 and 2 are summarized below.
As a result of the disclosure of the total number of involved ALN, a change in the indication occurred in 51 patients (16%). The most frequent change was a recommendation to ACT (35 patients, 69% of the changes). Among these patients, 9 changed from No-ACT to recommend ACT. All except one change in the indication to ACT occurred in patients with immunohistochemically defined Luminal A and Luminal B/HER2 negative tumors and were mostly towards ACT. Conclusions: Omission of AD in patients with a positive SLN receiving BCS would have altered the indication to ACT in 16% of the patients at our Institution. Changes occurred almost exclusively in patients with hormone receptor positive/HER2−negative tumors. The implications of omission of AD must be taken into account before its widespread acceptance, including the possibility of a biologically tailored surgical approach.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-07-04.
Collapse
Affiliation(s)
- F Montemurro
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - F Maggiorotto
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - G Valabrega
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - F Kubatzki
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - V Rossi
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - F Marocco
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - A Magistris
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - M Gatti
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - I Sarotto
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - M Aglietta
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| | - R Ponzone
- 1Fondazione del Piemonte per l'Oncologia/IRCC, Candiolo, Torino, Italy
| |
Collapse
|
65
|
Rossi V, Sarotto I, Maggiorotto F, Tomasi CN, Redana S, Aglietta M, Ponzone R, Montemurro F. P2-12-31: Moderate Immunohistochemical Expression of HER2 (2+) without HER2 Gene-Amplification Is a Negative Prognostic Factor in Early Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: We sought to evaluate whether moderate HER2 immunohistochemical (IHC) expression (2+ and no HER2/amplification) identifies early breast cancer (EBC) with a distinct prognostic profile.
Methods: A total of 1295 women (median age 58, range 22–94) undergoing surgery for EBC from Jan 1995 to Sept 2009 were retrospectively reviewed. All patients had undergone HER2 testing by the HercepTest and, when needed, by fluorescence in-situ hybridization (FISH). All tests were carried on at our Institutional Surgical Pathology laboratory. The impact of HER2 status on disease-free survival (DFS) was corrected for other clinical and pathological potential covariates by Cox Proportional Regression Analysis.
Results: A total of 494 (38%), 486 (38%), 119 (9%) and 196 (15%) of the patients had HER2 0+, 1+ 2+ and positive (3+ or FISH+) tumors, respectively. Sixty-one of 196 patients with HER2−positive EBC received adjuvant trastuzumab. A total of 298 DFS events occurred at median follow-up of 59 months (4-137 months). By using HER2 0+ status as reference, multivariate analysis revealed that HER2 2+ expression was associated with a significant increase in the risk of a DFS event (HR 2.303, 95% C.I. 1.501−3.533, p<0.001), whereas HER2 1+ was not (HR 0.976, 95% C.I. 0.698−1.365, p=0.889). We performed exploratory two-group comparisons by further classifying tumors according to hormone-receptor status (cutoff for ER and PgR positivity ≥10% of stained cells). Results are summarized in the table. HER2 2+ expression was associated with worse prognosis in both ER and/or PgR positive and ER/PgR negative tumors. In the latter group, HER2 2+ expression was associated with a particularly high rate of DFS events, with a 60-month projected DFS of 20%. Furthermore, while DFS curves plateaued at 60 months for HER2−positive tumors (with and without adjuvant trastuzumab) and for ER/PgR negative tumors with HER2 0/1+ expression, hormone receptor positive/HER2 2+ tumors displayed a particularly high rate of late relapses (beyond 60 months). Results did not change using a 1% cutoff to define ER and PgR positivity.
Conclusion: Moderate HER2 positivity (IHC 2+/FISH negative) identifies EBC patients at increased risk of a DFS event, regardless of hormone receptor status. Due to suggestions from large randomized trials that the benefits of trastuzumab may not be limited to HER2−positive tumors, patients with HER2 2+ EBC are ideal candidates for studies testing this hypothesis.
Multivariate Hazard Ratios, corrected by age, lymph-node status, tumor diameter, tumor grade, proliferation (Ki 67 index) and receipt of adjuvant chemotherapy
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-31.
Collapse
Affiliation(s)
- V Rossi
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - I Sarotto
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - F Maggiorotto
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - Cont N Tomasi
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - S Redana
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - M Aglietta
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - R Ponzone
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| | - F Montemurro
- 1Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy
| |
Collapse
|
66
|
Russo F, Mazzetti S, Grignani G, De Rosa G, Aglietta M, Anselmetti GC, Stasi M, Regge D. In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. Eur Radiol 2011; 22:1131-9. [DOI: 10.1007/s00330-011-2350-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2011] [Revised: 10/07/2011] [Accepted: 10/15/2011] [Indexed: 12/25/2022]
|
67
|
Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba10002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA10002 Background: Pazopanib, a multi targeted angiogenesis inhibitor, has demonstrated single-agent activity in pts with advanced STS. The efficacy and safety of pazopanib versus placebo as second or later line treatment were evaluated in pts with metastatic STS in a multi-center, international, double-blind, placebo-controlled phase III trial. Methods: Pts ≥18 years of age with angiogenesis inhibitor-naïve, histologically proven, metastatic STS, who failed at least one anthracycline containing regimen, could enter the study. They should have ≥1 measurable baseline lesion (per RECIST v1.0), WHO PS 0-1, adequate bone marrow, coagulation, hepatic and renal function, no poorly controlled hypertension, no bleeding diathesis, and no CNS involvement. The study has been conducted by EORTC and GSK in collaboration with 72 sarcoma centers worldwide. Pts were randomized 2:1 to receive either pazopanib 800 mg once daily or placebo until tumor progression, unacceptable toxicity, death, or pt’s request. Results: A total of 369 randomized pts (246 pazopanib, 123 placebo), median age of 56 years, participated in the study (EORTC 45 %, other 55%). Median duration of follow-up at clinical cut-off date is 15 months. The primary endpoint of progression-free survival (PFS) per independent review is significantly prolonged with pazopanib (median: 20 vs 7 weeks; HR=0.31, 95% CI 0.24-0.40 ; P<0.0001). The interim analysis for overall survival shows a statistically non-significant improvement of pazopanib vs placebo (median: 11.9 vs 10.4 months, HR=0.83, 95% CI 0.62-1.09). Main on-therapy grade 3-4 toxicities in the pazopanib vs placebo arm respectively: fatigue (13%, 6%), hypertension (7%, nil), anorexia (6%, nil), and diarrhea (5%, 1%). Similarly, thromboembolic events (grade 3-5 ) (3%, 2%), LVEF drop of >15% (8%, 3%). Median relative dose intensity of pazopanib was 768 mg daily. Conclusions: Pazopanib is an active drug in anthracycline pretreated metastatic STS pts with an increase in median PFS of 13 weeks.
Collapse
Affiliation(s)
- W. T. Van Der Graaf
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - J. Blay
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - S. P. Chawla
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - D. Kim
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - B. Bui Nguyen
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. G. Casali
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. Schöffski
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Aglietta
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. P. Staddon
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - Y. Beppu
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. Le Cesne
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - H. Gelderblom
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - I. R. Judson
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - N. Araki
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Ouali
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - S. Marreaud
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - R. Hodge
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Dewji
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. P. Dei Tos
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. Hohenberger
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| |
Collapse
|
68
|
Massimo B, Grignani G, Giostra A, Pagano M, Ferrari S, Elia BO, Carnevale-Scianca F, Aglietta M, Pellerito RE, Fagioli F. Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cell for patients with osteosarcoma with bone metastasis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
69
|
D'Ambrosio L, Ponzetti A, Lista P, Bombaci S, Palesandro E, Galizia D, Aliberti S, Allione P, Manca A, Gallo S, Grignani G, Aglietta M. Imatinib mesylate (IM) therapy in elderly patients affected by advanced gastrointestinal stromal tumor (GIST). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e20514] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
70
|
Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH, Bagalà C, Ferraro DA, Colombi F, Cagnazzo C, Gioeni L, Fly KD, Huang B, Leone F. Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naive patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
71
|
Galizia D, Ortega C, Palesandro E, Prati V, Gallo S, D'Ambrosio L, Bonzano A, Rota Scalabrini D, Aliberti S, Grignani G, Aglietta M. Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
72
|
Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P. PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba10002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
73
|
Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011; 104:1686-90. [PMID: 21540861 PMCID: PMC3111164 DOI: 10.1038/bjc.2011.151] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Vatalanib (PTK787/ZK 222584) inhibits a few tyrosine kinases including KIT, platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs). We report efficacy and safety results of vatalanib in advanced gastrointestinal stromal tumour (GIST) resistant to imatinib or both imatinib and sunitinib. PATIENTS AND METHODS Forty-five patients whose metastatic GIST had progressed on imatinib were enrolled. Nineteen (42.2%) patients had received also prior sunitinib. Vatalanib 1250 mg was administered orally daily. RESULTS Eighteen patients (40.0%; 95% confidence interval (CI), 25.7-54.3%) had clinical benefit including 2 (4.4%) confirmed partial remissions (PR; duration, 9.6 and 39.4 months) and 16 (35.6%) stabilised diseases (SDs; median duration, 12.5 months; range, 6.0-35.6+ months). Twelve (46.2%) out of the 26 patients who had received prior imatinib only achieved either PR or SD compared with 6 (31.6%, all SDs) out of the 19 patients who had received prior imatinib and sunitinib (P=0.324). The median time to progression was 5.8 months (95% CI, 2.9-9.5 months) in the subset without prior sunitinib and 3.2 (95% CI, 2.1-6.0) months among those with prior imatinib and sunitinib (P=0.992). Vatalanib was generally well tolerated. CONCLUSION Vatalanib is active despite its narrow kinome interaction spectrum in patients diagnosed with imatinib-resistant GIST or with imatinib and sunitinib-resistant GIST.
Collapse
Affiliation(s)
- H Joensuu
- Department of Oncology, University Central Hospital of Helsinki, Haartmaninkatu 4, Helsinki FIN-00029, Finland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
74
|
Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicolella D, Aglietta M, Lonardi S, Corsi D, Turci D, Beretta G, Fornarini G, Dapretto E, Floriani I, Zaniboni A. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised ‘GISCAD’ trial. Ann Oncol 2011; 22:1236-1242. [DOI: 10.1093/annonc/mdq580] [Citation(s) in RCA: 89] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
75
|
Grignani G, Palmerini E, Dileo P, Asaftei SD, D'Ambrosio L, Pignochino Y, Mercuri M, Picci P, Fagioli F, Casali PG, Ferrari S, Aglietta M. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2011; 23:508-16. [PMID: 21527590 DOI: 10.1093/annonc/mdr151] [Citation(s) in RCA: 257] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
PURPOSE After standard multimodal therapy, the prognosis of relapsed and unresectable high-grade osteosarcoma is dismal and unchanged over the last decades. Recently, mitogen-activated protein kinases were shown to be activated in osteosarcoma specimens, suggesting, therefore, they are suitable targets for the multikinase inhibitor sorafenib. Thus, we explored sorafenib activity in patients with relapsed and unresectable osteosarcoma. EXPERIMENTAL DESIGN Patients > 14 years, progressing after standard treatment, were eligible to receive 400 mg of sorafenib twice daily until progression or unacceptable toxicity. The primary end point was progression-free survival (PFS) at 4 months. Secondary objectives were PFS, overall survival (OS), clinical benefit rate (CBR), defined as no progression at 6 months and safety. This nonrandomized phase II study used a Simon two-stage design. PFS and OS at 95% confidence intervals (95% CIs) were calculated by the Kaplan-Meier method. All tests were two sided. RESULTS Thirty-five patients were enrolled. PFS at 4 months was 46% (95% CI 28% to 63%). Median PFS and OS were 4 (95% CI 2-5) and 7 (95% CI 7-8) months, respectively. The CBR was 29% (95% CI 13% to 44%). We observed 3 (8%) partial responses (PRs), 2 (6%) minor responses (< 30% tumor shrinkage) and 12 (34%) stable diseases (SDs). For six patients (17%), PR/SD lasted ≥ 6 months. Noteworthy, tumor density reduction and [(18)F]2-fluoro-2-deoxy-d-glucose-positron emission tomography responses were observed among SD patients. Sorafenib was reduced or briefly interrupted in 16 (46%) patients and permanently discontinued in one (3%) case due to toxicity. CONCLUSIONS Sorafenib demonstrated activity as a second- or third-line treatment in terms of PFS at 4 months with some unprecedented long-lasting responses. Sorafenib, the first targeted therapy showing activity in osteosarcoma patients, deserves further investigations.
Collapse
Affiliation(s)
- G Grignani
- Medical Oncology Unit, Institute for Cancer Research and Treatment, Candiolo, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Abstract
231 Background: Biliary carcinoma (BC) has a poor prognosis and limited therapeutic options. The identification of new targets is essential. Among candidates we have studied the tyrosine kinase Src, which is involved in proliferation, invasion, and migration in many tumors.It has been demonstrated that the inhibition of Src significantly reduces proliferation and metastasis development in different solid tumors, such as pancreatic and head and neck cancers. Targeting Src tyrosine kinase may be therapeuticallyuseful in cholangiocarcinoma. We explored the antitumor activity of Src inhibitor saracatinib (AZD-0530) in BC preclinical models. Methods: Four cholangiocarcinoma cell lines, TFK1, EGI-1, HuH28, and TGBC1-TKB, were treated with saracatinib and analyzed by western blot for the expression of Src and its downstream principal transducer FAK. The inhibition of proliferation was evaluated by cell titer glo assay after treatment with scalar doses of saracatinib alone or in combination with gemcitabine for 72 hours. The effect on migration of BC cells was tested by wound healing assay. Finally, we investigated the antitumor activity in EGI-1 xenografts in NOD/Shi-scidIL2rgnull mice treated with saracatinib at 10 mg/kg/die. Results: Activation of Src pathaway was shown in all cell lines and saracatinib was able to inhibit its downstream molecules. Saracatinib inhibited BC cell proliferation in standard monolayer liquid culture only at very high concentration (median doses from 2.5 to 15 μM) and did not enhance the antiproliferative effect of gemcitabine. Evidence of anti-tumor activity of saracatinib was obtained in terms of migration inhibition: quantitation of the wound closure over time revealed a significant and dose-dependent inhibitory effect of saracatinib on BC cell motility. In the in vivo model, no reduction of tumor volumes was evidenced up to 14 days of treatment. Assays with prolonged treatments are ongoing. Conclusions: These results suggest that inhibition of Src kinase by saracatinib impairs the invasiveness of bile duct carcinoma. Further in vivo studies will provide information about the effect on metastasis inhibition by saracatinib. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Leone
- Medical Oncology, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy; Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy; Institute for Cancer Research and Treatment, Candiolo, Italy
| | - C. Peraldo-Neia
- Medical Oncology, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy; Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy; Institute for Cancer Research and Treatment, Candiolo, Italy
| | - G. Cavalloni
- Medical Oncology, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy; Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy; Institute for Cancer Research and Treatment, Candiolo, Italy
| | - F. Colombi
- Medical Oncology, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy; Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy; Institute for Cancer Research and Treatment, Candiolo, Italy
| | - M. Aglietta
- Medical Oncology, Institute for Cancer Research and Treatment, University of Turin, Candiolo, Italy; Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy; Institute for Cancer Research and Treatment, Candiolo, Italy
| |
Collapse
|
77
|
Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011; 22:1614-1621. [PMID: 21245159 DOI: 10.1093/annonc/mdq703] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Outcomes of Ewing tumor (ET) patients treated with allogeneic stem cell transplantation (allo-SCT) were compared regarding the use of reduced-intensity conditioning (RIC) and high-intensity conditioning (HIC) regimens as well as human leukocyte antigen (HLA)-matched and HLA-mismatched grafts. PATIENTS AND METHODS We retrospectively analyzed data of 87 ET patients from the European Group for Blood and Marrow Transplantation, Pediatric Registry for Stem Cell Transplantations, Asia Pacific Blood and Marrow Transplantation and MetaEICESS registries treated with allo-SCT. Fifty patients received RIC (group A) and 37 patients received HIC (group B). Twenty-four patients received HLA-mismatched grafts and 63 received HLA-matched grafts. RESULTS Median overall survival was 7.9 months [±1.24, 95% confidence interval (CI) 5.44-10.31] for group A and 4.4 months (±1.06, 95% CI 2.29-6.43) for group B patients (P = 1.3). Death of complications (DOC) occurred in 4 of 50 (0.08) and death of disease (DOD) in 33 of 50 (0.66) group A and in 16 of 37 (0.43) and 17 of 37 (0.46) group B patients, respectively. DOC incidence was decreased (P < 0.01) and DOD/relapse increased (P < 0.01) in group A compared with group B. HLA mismatch was not generally associated with graft-versus-Ewing tumor effect (GvETE). CONCLUSIONS There was no improvement of survival with RIC compared with HIC due to increased DOD/relapse incidence after RIC despite less DOC incidence. This implicates general absence of a clinically relevant GvETE with current protocols.
Collapse
Affiliation(s)
- U Thiel
- Department of Pediatrics and Wilhelm Sander Sarcoma Unit MRI, Pediatric Oncology Center, Technische Universität München
| | - A Wawer
- Department of Pediatrics and Wilhelm Sander Sarcoma Unit MRI, Pediatric Oncology Center, Technische Universität München
| | - P Wolf
- Institute for Medical Statistics and Epidemiology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
| | - M Badoglio
- EBMT Data & Study Office, Hopital Saint-Antoine, Assistance Publique des Hôpitaux de Paris and UPMC Univ Paris 06, Paris, France
| | - A Santucci
- Section of Pediatric Hematology & Oncology, University of Perugia, Perugia, Italy
| | - T Klingebiel
- Children's Hospital III, Department of Pediatrics, Johann Wolfgang Goethe University, Frankfurt
| | - O Basu
- Children's Hospital III, Department of Pediatrics, Johann Wolfgang Goethe University, Frankfurt
| | - A Borkhardt
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany
| | - H-J Laws
- Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany
| | - Y Kodera
- Department of Promotion for Blood and Marrow Transplantation, Aichi Medical University, Aichi; APBMT Data Center, Nagoya University School of Medicine, Nagoya, Japan
| | - A Yoshimi
- APBMT Data Center, Nagoya University School of Medicine, Nagoya, Japan
| | - C Peters
- Department of Pediatrics, St. Anna Kinderspital, Vienna, Austria
| | - R Ladenstein
- Department of Pediatrics, St. Anna Kinderspital, Vienna, Austria
| | - A Pession
- Department of Scienze Pediatriche Mediche e Chirurgiche, Ospedale S Orsola Malpighi, Bologna, Italy
| | - A Prete
- Department of Scienze Pediatriche Mediche e Chirurgiche, Ospedale S Orsola Malpighi, Bologna, Italy
| | - E-C Urban
- Department of Pediatrics, Medical University of Graz, Graz, Austria
| | - W Schwinger
- Department of Pediatrics, Medical University of Graz, Graz, Austria
| | - P Bordigoni
- Service de Transplantation Medullaire, CHU de Nancy Brabois, Vandoeuvre-les-Nancy, France
| | - A Salmon
- Service de Transplantation Medullaire, CHU de Nancy Brabois, Vandoeuvre-les-Nancy, France
| | - M A Diaz
- Department of Pediatrics, Division of Pediatric Hematology-Oncology and Hematopoietic Stem Cell Transplantation and Cell Therapy Unit, Hospital Infantil Universitario Niño Jesus, Madrid, Spain
| | - B Afanasyev
- St. Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children`s Institute, Department of Hematology and Transplantology, St. Petersburg, Russia
| | - I Lisukov
- St. Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children`s Institute, Department of Hematology and Transplantology, St. Petersburg, Russia
| | - E Morozova
- St. Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children`s Institute, Department of Hematology and Transplantology, St. Petersburg, Russia
| | - A Toren
- Pediatric Hemato-Oncology Unit, Sheba Medical Center (affiliated to the Sackler Faculty of Medicine), Tel Hashomer, Israel
| | - B Bielorai
- Pediatric Hemato-Oncology Unit, Sheba Medical Center (affiliated to the Sackler Faculty of Medicine), Tel Hashomer, Israel
| | - J Korsakas
- Department of Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskiu Clinics, Vilnius, Lithuania
| | - F Fagioli
- Stem Cell Transplantation and Cellular Therapy Unit, Pediatric Onco-Hematology Division, "Regina Margherita" Children's Hospital, Turin
| | - D Caselli
- Department of Oncoematologia Pediatrica, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy
| | - G Ehninger
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden
| | - B Gruhn
- Department of Pediatrics, University of Jena, Jena
| | - U Dirksen
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - F Abdel-Rahman
- The Bone Marrow and Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan
| | - M Aglietta
- Department of Istituto per la Ricerca e la Cura del Cancro, Turin, Italy
| | - E Mastrodicasa
- Section of Pediatric Hematology & Oncology, University of Perugia, Perugia, Italy
| | - M Torrent
- Hospital de la Santa Creu i Sant Pau, Department of Pediatrics, Barcelona, Spain
| | - P Corradini
- Department of Hematology - Bone Marrow Transplantation Unit, Istituto Nazionale dei Tumori, University of Milano, Milan, Italy
| | - F Demeocq
- Centre Hospitalier et Universitaire de Clermont-Ferrand, Service de Pédiatrie B et Unité Bioclinique de Thérapie Cellulaire, Clermont-Ferrand, France
| | - G Dini
- Department of UO Ematologia ed Oncologia Pediatrica, Istituto G Gaslini, Genova, Italy
| | - P Dreger
- Department of Internal Medicine V, University of Heidelberg, Heidelberg
| | - M Eyrich
- Children's Hospital, Department of Paediatric Stem Cell Transplantation, University of Würzburg, Würzburg, Germany
| | - J Gozdzik
- Transplantation Centre, University Children's Hospital, Cracow, Poland
| | - F Guilhot
- Department of Hematology, University Hospital, Poitiers, France
| | - E Holler
- Department of Hematology and Oncology, University of Regensburg, Regensburg
| | - E Koscielniak
- Department of Pediatrics 5 (Oncology, Hematology, Immunology), Olga Hospital, Klinikum Stuttgart, Stuttgart, Germany
| | - C Messina
- Hemo/Oncology, Department of Pediatrics, Hospital-University of Padova, Padova, Italy
| | - D Nachbaur
- University Hospital of Innsbruck, Internal Medicine V, Department of Hematology and Oncology, Innsbruck, Austria
| | - R Sabbatini
- Department of Oncology, Haematology, and Respiratory Diseases, Policlinico di Modena, Modena
| | - E Oldani
- Department of U.S.C. Ematologia, Ospedali Riuniti, Bergamo, Italy
| | - H Ottinger
- Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
| | - H Ozsahin
- Paediatric Oncology Unit, University of Geneva Children's Hospital, Geneva, Switzerland
| | - R Schots
- Division of Clinical Hematology and BMT Unit, University Hospital Brussels, Brussels, Belgium
| | - S Siena
- Department of S. C. Divisione Oncologia Falck and S. C. Divisione Anatomia Patologica, Ospedale Niguarda Ca' Granda, Milan, Italy
| | - J Stein
- Bone marrow Transplant Unit, Department of Pediatric Hematology-Oncology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
| | - S Sufliarska
- Bone Marrow Transplantation Unit, Department of Pediatrics, Comenius University Medical School, Bratislava, Slovak Republic
| | - A Unal
- Institutions Erciyes Medical School, Department of Hematology and Oncology, Kapadokya BMT Center, Kayseri, Turkey
| | - M Ussowicz
- Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
| | - P Schneider
- Department of Pediatric Hematology and Oncology, Hôpital Charles Nicolle, Rouen, France
| | - W Woessmann
- Department of Pediatric Hematology and Oncology, University Hospital, Giessen, Germany
| | - H Jürgens
- Department of Pediatric Hematology and Oncology, University Children's Hospital, Münster, Germany
| | - M Bregni
- Unit of Medical Oncology, Ospedale San Giuseppe, Milan, Italy
| | - S Burdach
- Department of Pediatrics and Wilhelm Sander Sarcoma Unit MRI, Pediatric Oncology Center, Technische Universität München.
| | | | | | | |
Collapse
|
78
|
Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nolè F. Abstract PD10-07: Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd10-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hormone receptors (HR) and the human epidermal growth factor receptor 2 (HER2) are key biological factors in breast cancer. Gene expression profile studies indicate that HER2-positive/HR-positive and HER2-positive/HR-negative tumors fall into two distinct subtypes. These two subtypes carry a different prognosis in the absence of HER2-targeting. Furthermore, a relationship has been documented between increasing HR expression and reduced chemoresponsiveness. Despite these differences, HER2-positive abvanced breast cancer patients are usually treated with a unified approach of combining chemotherapy with an HER2-targeting agent, regardless of HR status. We studied the association between hormone receptor (HR) expression and the clinical outcome of women with HER2-positive advanced breast cancer receiving chemotherapy plus trastuzumab.
Methods: The effect of HR expression on overall response rate (ORR) and progression-free survival (PFS) to trastuzumab-based treatment was studied by univariate and multivariate analysis. HR positivity was defined as 1% or more tumor cells positive for the estrogen (ER) and/or for the progesterone (PgR) receptor by immunohistochemistry. For both ER and PgR, we studied different thresholds to identify levels of expression associated with the clinical outcomes of interest.
Results: 227 consecutive advanced breast cancer patients receiving trastuzumab plus chemotherapy between June 1999 and November 2008 at two Institutions were retrospectively analyzed. One hundred eleven patients (49%) had HR-positive tumors. Compared with low or no expression, high expression of ER (30% or more) predicted reduced probability of tumor response to trastuzumab plus chemotherapy (multivariate odds ratio 0.422, 95% confidence interval-C.I. 0.222-0.803, p = 0.009). In patients with HR-positive tumors the addition of maintenance endocrine therapy to trastuzumab after the completion of chemotherapy was associated with a significant increase in progression-free survival (hazard ratio-HR 0.521, 95% C.I. 0.3325-0.836, p = 0.007). Patients with HR-positive tumors not receiving maintenance endocrine therapy had similar PFS than patients with HR-negative tumors (HR 0.914, 95% C.I. 0.654-1.279, p = 0.601). In patients not receiving maintenance endocrine therapy, high ER expression (30% or more cells) was associated with non-significant trend towards reduced risk of progression, compared with patients with low or absent ER expression (HR 0.747, 95% C.I. 0.516-1.081, p = 0.122). Conclusions: Our results suggest a predictive role of HR expression in HER2-positive tumors. Further investigation in this patient subset is warranted to optimize the use of HER2-targeting agents, chemotherapy and endocrine therapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD10-07.
Collapse
Affiliation(s)
- F Montemurro
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - V Rossi
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - M Cossu Rocca
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - R Martinello
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - E Verri
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - S Redana
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - L Adamoli
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - G Valabrega
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - A Sapino
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - M Aglietta
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - G Viale
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - A Goldhirsch
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - F. Nolè
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| |
Collapse
|
79
|
Karoui M, Vigano L, Goyer P, Ferrero A, Luciani A, Aglietta M, Delbaldo C, Cirillo S, Capussotti L, Cherqui D. Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. Br J Surg 2010; 97:1354-62. [PMID: 20603857 DOI: 10.1002/bjs.7128] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND This study assessed the feasibility and outcomes of combined colorectal and hepatic resection as the first step of two-stage hepatectomy in patients with bilobar synchronous colorectal liver metastases. METHODS All patients with bilobar synchronous colorectal liver metastases who were considered for two-stage hepatectomy, combining resection of the primary tumour with the first stage of hepatectomy, between 2000 and 2008 were selected from a prospectively collected database at two institutions. Data were analysed retrospectively on an intention-to-treat basis. RESULTS Thirty-three patients were studied. Twenty patients received neoadjuvant chemotherapy. Combined colorectal resection and clearance of left-sided liver metastases was the first-stage procedure in all but one patient, in whom right clearance was performed. In 17 patients right portal vein ligation was undertaken at the same time. No patient died. Two patients had anastomotic leakage. Interval chemotherapy was given to 25 patients, five of whom also had percutaneous portal vein embolization. Twenty-five patients had the second-stage hepatectomy, but not eight patients with disease progression. There was one postoperative death after the second stage, and eight patients experienced morbidity. Median follow-up from the first stage was 28.7 months. Overall and disease-free survival rates for patients who completed the procedure were 80 and 44 per cent respectively at 3 years, and 48 and 22 per cent at 5 years. CONCLUSION In patients with bilobar synchronous colorectal liver metastases who are candidates for two-stage hepatectomy, combined resection of the primary tumour and first-stage hepatectomy reduces the number of procedures, optimizes chemotherapy administration and may improve outcome.
Collapse
Affiliation(s)
- M Karoui
- Department of Digestive and Hepatobiliary Surgery, Assistance Publique-Hôpitaux de Paris, Henri Mondor University Hospital, Créteil, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
80
|
Pignochino Y, Inghilleri S, Zorzetto M, Luisetti M, Morbini P, Aglietta M, Pozzi E, Stella G. 133 mTOR is a druggable molecule in Malignant Pleural Mesothelioma targeted therapy: antiproliferative effect of sorafenib and everolimus in preclinical models. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70941-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
81
|
D'Ambrosio L, Galizia D, Aliberti S, Ferraris R, Rota Scalabrini D, Fizzotti M, Caravelli D, Palesandro E, Grignani G, Aglietta M. High-grade soft tissue sarcomas (STS) of elderly (≥70 years) patients (E-STS): Feasibility and morbidity of anthracycline-based chemotherapy (A-CT) in a selected subset of patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e20515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
82
|
Grignani G, Palmerini E, Stacchiotti S, Boglione A, Ferraresi V, Frustaci S, Comandone A, Casali PG, Ferrari S, Aglietta M. A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-α or -β (PDGFR-α/PDGFR-β): An Italian Sarcoma Group study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10060] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
83
|
Pignochino Y, Grignani G, Basiricò M, Cavalloni G, Motta M, Bruno S, Aliberti S, Alberghini M, Picci P, Aglietta M. Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
84
|
Rossi V, Nole F, Redana S, Donadio M, Martinello R, Verri E, Valabrega G, Cossu Rocca M, Aglietta M, Montemurro F. Underuse of anthracyclines in women with HER2-positive advanced breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
85
|
Aglietta M, Barone C, Muliello M, Bagalà C, Ferraro D, Fly KD, Huang B, Leone F. A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4134] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
86
|
Abraham J, Abreu P, Aglietta M, Ahn EJ, Allard D, Allekotte I, Allen J, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anticić T, Anzalone A, Aramo C, Arganda E, Arisaka K, Arqueros F, Asorey H, Assis P, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Balzer M, Barber KB, Barbosa AF, Barroso SLC, Baughman B, Bauleo P, Beatty JJ, Becker BR, Becker KH, Bellétoile A, Bellido JA, Benzvi S, Berat C, Bergmann T, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blanco M, Bleve C, Blümer H, Bohácová M, Boncioli D, Bonifazi C, Bonino R, Borodai N, Brack J, Brogueira P, Brown WC, Bruijn R, Buchholz P, Bueno A, Burton RE, Busca NG, Caballero-Mora KS, Caramete L, Caruso R, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chudoba J, Clay RW, Colombo E, Coluccia MR, Conceição R, Contreras F, Cook H, Cooper MJ, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Dallier R, Daumiller K, Dawson BR, de Almeida RM, De Domenico M, De Donato C, de Jong SJ, De La Vega G, de Mello Junior WJM, de Mello Neto JRT, De Mitri I, de Souza V, de Vries KD, Decerprit G, Del Peral L, Deligny O, Della Selva A, Delle Fratte C, Dembinski H, Di Giulio C, Diaz JC, Díaz Castro ML, Diep PN, Dobrigkeit C, D'Olivo JC, Dong PN, Dorofeev A, Dos Anjos JC, Dova MT, D'Urso D, Dutan I, Duvernois MA, Ebr J, Engel R, Erdmann M, Escobar CO, Etchegoyen A, Facal San Luis P, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferrero A, Fick B, Filevich A, Filipcic A, Fleck I, Fliescher S, Fracchiolla CE, Fraenkel ED, Fröhlich U, Fulgione W, Gamarra RF, Gambetta S, García B, García Gámez D, Garcia-Pinto D, Garrido X, Gelmini G, Gemmeke H, Ghia PL, Giaccari U, Giller M, Glass H, Goggin LM, Gold MS, Golup G, Gomez Albarracin F, Gómez Berisso M, Gonçalves P, Gonzalez D, Gonzalez JG, Góra D, Gorgi A, Gouffon P, Gozzini SR, Grashorn E, Grebe S, Grigat M, Grillo AF, Guardincerri Y, Guarino F, Guedes GP, Hague JD, Halenka V, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hebbeker T, Heck D, Herve AE, Hojvat C, Holmes VC, Homola P, Hörandel JR, Horneffer A, Hrabovský M, Huege T, Hussain M, Iarlori M, Insolia A, Ionita F, Italiano A, Jiraskova S, Kadija K, Kaducak M, Kampert KH, Karova T, Kasper P, Kégl B, Keilhauer B, Keivani A, Kelley J, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Krieger A, Krömer O, Kruppke-Hansen D, Kuehn F, Kuempel D, Kulbartz K, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lautridou P, Leão MSAB, Lebrun D, Lebrun P, Lee J, Leigui de Oliveira MA, Lemiere A, Letessier-Selvon A, Lhenry-Yvon I, López R, Lopez Agüera A, Louedec K, Lozano Bahilo J, Lucero A, Ludwig M, Lyberis H, Maccarone MC, Macolino C, Maldera S, Mandat D, Mantsch P, Mariazzi AG, Marin V, Maris IC, Marquez Falcon HR, Marsella G, Martello D, Martínez Bravo O, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, McEwen M, Medina-Tanco G, Melissas M, Melo D, Menichetti E, Menshikov A, Meurer C, Micanović S, Micheletti MI, Miller W, Miramonti L, Mollerach S, Monasor M, Monnier Ragaigne D, Montanet F, Morales B, Morello C, Moreno E, Moreno JC, Morris C, Mostafá M, Mueller S, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Nhung PT, Nierstenhoefer N, Nitz D, Nosek D, Nozka L, Nyklicek M, Oehlschläger J, Olinto A, Oliva P, Olmos-Gilbaja VM, Ortiz M, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Palmieri N, Parente G, Parizot E, Parlati S, Parra A, Parrisius J, Parsons RD, Pastor S, Paul T, Pavlidou V, Payet K, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Pesce R, Petermann E, Petrera S, Petrinca P, Petrolini A, Petrov Y, Petrovic J, Pfendner C, Piegaia R, Pierog T, Pimenta M, Pirronello V, Platino M, Ponce VH, Pontz M, Privitera P, Prouza M, Quel EJ, Rautenberg J, Ravel O, Ravignani D, Redondo A, Revenu B, Rezende FAS, Ridky J, Riggi S, Risse M, Ristori P, Rivière C, Rizi V, Robledo C, Rodriguez G, Rodriguez Martino J, Rodriguez Rojo J, Rodriguez-Cabo I, Rodríguez-Frías MD, Ros G, Rosado J, Rossler T, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos E, Santos EM, Sarazin F, Sarkar S, Sato R, Scharf N, Scherini V, Schieler H, Schiffer P, Schmidt A, Schmidt F, Schmidt T, Scholten O, Schoorlemmer H, Schovancova J, Schovánek P, Schroeder F, Schulte S, Schüssler F, Schuster D, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shadkam A, Shellard RC, Sidelnik I, Siffert BB, Sigl G, Smiałkowski A, Smída R, Snow GR, Sommers P, Sorokin J, Spinka H, Squartini R, Stasielak J, Stephan M, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Susa T, Sutherland MS, Swain J, Szadkowski Z, Tamashiro A, Tamburro A, Tapia A, Tarutina T, Taşcău O, Tcaciuc R, Tcherniakhovski D, Tegolo D, Thao NT, Thomas D, Tiffenberg J, Timmermans C, Tkaczyk W, Todero Peixoto CJ, Tomé B, Tonachini A, Travnicek P, Tridapalli DB, Tristram G, Trovato E, Tueros M, Ulrich R, Unger M, Urban M, Valdés Galicia JF, Valiño I, Valore L, van den Berg AM, Vázquez JR, Vázquez RA, Veberic D, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wahrlich P, Wainberg O, Warner D, Watson AA, Westerhoff S, Whelan BJ, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Williams C, Winchen T, Winnick MG, Wundheiler B, Yamamoto T, Younk P, Yuan G, Yushkov A, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Ziolkowski M. Measurement of the depth of maximum of extensive air showers above 10{18} eV. Phys Rev Lett 2010; 104:091101. [PMID: 20366976 DOI: 10.1103/physrevlett.104.091101] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2009] [Indexed: 05/29/2023]
Abstract
We describe the measurement of the depth of maximum, X{max}, of the longitudinal development of air showers induced by cosmic rays. Almost 4000 events above 10;{18} eV observed by the fluorescence detector of the Pierre Auger Observatory in coincidence with at least one surface detector station are selected for the analysis. The average shower maximum was found to evolve with energy at a rate of (106{-21}{+35}) g/cm{2}/decade below 10{18.24+/-0.05} eV, and (24+/-3) g/cm{2}/decade above this energy. The measured shower-to-shower fluctuations decrease from about 55 to 26 g/cm{2}. The interpretation of these results in terms of the cosmic ray mass composition is briefly discussed.
Collapse
Affiliation(s)
- J Abraham
- National Technological University, Faculty Mendoza (CONICET/CNEA), Mendoza, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
87
|
Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 2009; 9:831-40. [PMID: 19463075 DOI: 10.1517/14712590903005552] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Donor lymphocyte infusion (DLI) is used to increase the graft versus tumor (GVT) effect after allogeneic hematopoietic cell transplant (HCT). The limited spectrum of activity and high risk of graft versus host disease (GVHD) remain major limitations of this approach. The finding of new cell populations for adoptive immunotherapy, with the ability to separate GVT from GVHD, would be useful. Here we review the main basic, preclinical and clinical research on cytokine-induced killer (CIK) cells, highlighting the aspects of their antitumor and alloreactive potentials that might favourably affect the balance between GVT and GVHD. CIK cells are ex vivo-expanded T lymphocytes sharing NK markers and endowed with a potent MHC-unrestricted antitumor activity against haematological and solid malignancies. Studies in preclinical animal models have demonstrated their low GVHD potential when infused across MHC-barriers, and recent clinical studies seem to confirm these findings in patients with hematological malignancies relapsing after HCT. If consolidated with larger clinical trials, adoptive immunotherapy with CIK cells might represent an effective alternative to classic DLI, helping HCT to succesfully meet current challenges like the extension across major HLA-barriers and application to solid tumors.
Collapse
Affiliation(s)
- D Sangiolo
- Institute for Cancer Research and Treatment (IRCC), Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo (TO), Italy.
| | | | | | | | | | | |
Collapse
|
88
|
Berger M, Grignani G, Ferrari S, Biasin E, Brach del Prever A, Aliberti S, Saglio F, Aglietta M, Fagioli F. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. Cancer 2009; 115:2980-7. [PMID: 19452540 DOI: 10.1002/cncr.24368] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND A phase 2 trial was carried out to assess the antineoplastic activity of 2 courses of cyclophosphamide-etoposide in relapsed osteosarcoma patients. METHODS Twenty-six relapsed osteosarcoma patients with a median age of 18.5 years (8.3-47.1) were enrolled. Seven patients were in first relapse (27%), 11 in second relapse (42%), 7 in third relapse (27%), and 1 in fourth relapse (4%). Eighteen patients had bone metastasis at study entry (69%). Cyclophosphamide was given at 4 g/m(2) on Day 1 followed by etoposide at 200 mg/m(2) on Days 2, 3, and 4. Second cyclophosphamide and etoposide was planned at 21 days to 28 days from the previous one. The primary endpoint of the study was the clinical benefit at 4 months measured as progression-free survival. RESULTS Progression-free survival at 4 months was 42%. Five patients achieved responses (19%), 9 patients had stable disease (35%), and 12 had tumor progression (46%). Overall survival (OS) at 1 year was 50%. The only grade 4 extrahematological toxicities were fever (5%), acute bronchospasm (4%) and stomatitis (18%). Six patients (23%) underwent radical surgery after cyclophosphamide and etoposide x2. CONCLUSIONS Cyclophosphamide and etoposide x2 may arrest osteosarcoma progression in a significant number of patients (54%). Osteosarcoma progression arrest after cyclophosphamide and etoposide x2 translates in a better OS. Cyclophosphamide and etoposide x2 had good tolerability and the toxicity was time-limited and resolved in all cases.
Collapse
Affiliation(s)
- M Berger
- Oncoematologia Pediatrica, Regina Margherita Children's Hospital, Torino, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
89
|
Ortega C, Faggiuolo R, Vormola R, Montemurro F, Nanni D, Goia F, Aglietta M. Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta Oncol 2009; 45:216-7. [PMID: 16546871 DOI: 10.1080/02841860500341173] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
90
|
Fagioli F, Biasin E, Mereuta OM, Muraro M, Luksch R, Ferrari S, Aglietta M, Madon E. Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant 2008; 41 Suppl 2:S131-4. [PMID: 18545234 DOI: 10.1038/bmt.2008.71] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Over the past 30 years, a significant improvement in the prognosis of localized osteosarcoma of the extremities has been observed. Despite these results, approximately 30-40% of patients will relapse, mostly within the first 3 years from diagnosis. The prognosis of patients with recurrent disease or metastases at diagnosis is poor. To improve the survival in this patient population, several attempts have been made. An increased dose intensity of chemotherapy induces short lasting remission but does not increase the survival. In the era of targeted therapy, few drugs have been tested with dismal results. The use of biological agents endowed with immunomodulant activity (that is IL-2) or reduced-intensity allogeneic hemopoietic SCT has produced intriguing results that need further confirmation. In this context, an ongoing study explores the antitumor activity of specific T-cytotoxic lymphocytes.
Collapse
Affiliation(s)
- F Fagioli
- Stem Cell Transplantation and Cellular Therapy Unit, Regina Margherita Children's Hospital, Turin, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
91
|
Abraham J, Abreu P, Aglietta M, Aguirre C, Allard D, Allekotte I, Allen J, Allison P, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anzalone A, Aramo C, Argirò S, Arisaka K, Armengaud E, Arneodo F, Arqueros F, Asch T, Asorey H, Assis P, Atulugama BS, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Barbosa AF, Barnhill D, Barroso SLC, Baughman B, Bauleo P, Beatty JJ, Beau T, Becker BR, Becker KH, Bellido JA, Benzvi S, Berat C, Bergmann T, Bernardini P, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blasi P, Bleve C, Blümer H, Bohácová M, Bonifazi C, Bonino R, Brack J, Brogueira P, Brown WC, Buchholz P, Bueno A, Burton RE, Busca NG, Caballero-Mora KS, Cai B, Camin DV, Caramete L, Caruso R, Carvalho W, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chudoba J, Chye J, Clark PDJ, Clay RW, Colombo E, Conceição R, Connolly B, Contreras F, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Daumiller K, Dawson BR, de Almeida RM, De Donato C, de Jong SJ, De La Vega G, Junior WJMDM, Neto JRTDM, De Mitri I, de Souza V, Del Peral L, Deligny O, Della Selva A, Fratte CD, Dembinski H, Di Giulio C, Diaz JC, Diep PN, Dobrigkeit C, D'Olivo JC, Dong PN, Dornic D, Dorofeev A, Dos Anjos JC, Dova MT, D'Urso D, Dutan I, Duvernois MA, Engel R, Epele L, Erdmann M, Escobar CO, Etchegoyen A, Luis PFS, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferrer F, Ferrero A, Fick B, Filevich A, Filipcic A, Fleck I, Fracchiolla CE, Fulgione W, García B, Gámez DG, Garcia-Pinto D, Garrido X, Geenen H, Gelmini G, Gemmeke H, Ghia PL, Giller M, Glass H, Gold MS, Golup G, Albarracin FG, Berisso MG, Gonçalves P, do Amaral MG, Gonzalez D, Gonzalez JG, González M, Góra D, Gorgi A, Gouffon P, Grassi V, Grillo AF, Grunfeld C, Guardincerri Y, Guarino F, Guedes GP, Gutiérrez J, Hague JD, Halenka V, Hamilton JC, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hauschildt T, Healy MD, Hebbeker T, Hebrero G, Heck D, Hojvat C, Holmes VC, Homola P, Hörandel JR, Horneffer A, Hrabovský M, Huege T, Hussain M, Iarlori M, Insolia A, Ionita F, Italiano A, Kaducak M, Kampert KH, Karova T, Kasper P, Kégl B, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Krieger A, Krömer O, Kuempel D, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lebrun D, Lebrun P, Lee J, de Oliveira MAL, Letessier-Selvon A, Leuthold M, Lhenry-Yvon I, López R, Agüera AL, Bahilo JL, Lucero A, García RL, Maccarone MC, Macolino C, Maldera S, Mancarella G, Manceñido ME, Mandat D, Mantsch P, Mariazzi AG, Maris IC, Falcon HRM, Martello D, Martínez J, Bravo OM, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, McCauley T, McEwen M, McNeil RR, Medina MC, Medina-Tanco G, Melo D, Menichetti E, Menschikov A, Meurer C, Meyhandan R, Micheletti MI, Miele G, Miller W, Mollerach S, Monasor M, Ragaigne DM, Montanet F, Morales B, Morello C, Moreno JC, Morris C, Mostafá M, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Newman-Holmes C, Newton D, Nhung PT, Nierstenhoefer N, Nitz D, Nosek D, Nozka L, Oehlschläger J, Ohnuki T, Olinto A, Olmos-Gilbaja VM, Ortiz M, Ortolani F, Ostapchenko S, Otero L, Pacheco N, Selmi-Dei DP, Palatka M, Pallotta J, Parente G, Parizot E, Parlati S, Pastor S, Patel M, Paul T, Pavlidou V, Payet K, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Pesce R, Petrera S, Petrinca P, Petrov Y, Pichel A, Piegaia R, Pierog T, Pimenta M, Pinto T, Pirronello V, Pisanti O, Platino M, Pochon J, Privitera P, Prouza M, Quel EJ, Rautenberg J, Redondo A, Reucroft S, Revenu B, Rezende FAS, Ridky J, Riggi S, Risse M, Rivière C, Rizi V, Roberts M, Robledo C, Rodriguez G, Martino JR, Rojo JR, Rodriguez-Cabo I, Rodríguez-Frías MD, Ros G, Rosado J, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos EM, Sarazin F, Sarkar S, Sato R, Scherini V, Schieler H, Schmidt A, Schmidt F, Schmidt T, Scholten O, Schovánek P, Schroeder F, Schulte S, Schüssler F, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shellard RC, Sidelnik I, Siffert BB, Sigl G, Grande NSD, Smiałkowski A, Smída R, Smith AGK, Smith BE, Snow GR, Sokolsky P, Sommers P, Sorokin J, Spinka H, Squartini R, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Takahashi J, Tamashiro A, Tamburro A, Tarutina T, Taşcău O, Tcaciuc R, Thao NT, Thomas D, Ticona R, Tiffenberg J, Timmermans C, Tkaczyk W, Peixoto CJT, Tomé B, Tonachini A, Torres I, Travnicek P, Tripathi A, Tristram G, Tscherniakhovski D, Tuci V, Tueros M, Tunnicliffe V, Ulrich R, Unger M, Urban M, Galicia JFV, Valiño I, Valore L, van den Berg AM, van Elewyck V, Vázquez RA, Veberic D, Veiga A, Velarde A, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wahrlich P, Wainberg O, Walker P, Warner D, Watson AA, Westerhoff S, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Wileman C, Winnick MG, Wu H, Wundheiler B, Yamamoto T, Younk P, Zas E, Zavrtanik D, Zavrtanik M, Zaw I, Zepeda A, Ziolkowski M. Observation of the suppression of the flux of cosmic rays above 4 x 10 (19) eV. Phys Rev Lett 2008; 101:061101. [PMID: 18764444 DOI: 10.1103/physrevlett.101.061101] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/11/2008] [Indexed: 05/26/2023]
Abstract
The energy spectrum of cosmic rays above 2.5 x 10;{18} eV, derived from 20,000 events recorded at the Pierre Auger Observatory, is described. The spectral index gamma of the particle flux, J proportional, variantE;{-gamma}, at energies between 4 x 10;{18} eV and 4 x 10;{19} eV is 2.69+/-0.02(stat)+/-0.06(syst), steepening to 4.2+/-0.4(stat)+/-0.06(syst) at higher energies. The hypothesis of a single power law is rejected with a significance greater than 6 standard deviations. The data are consistent with the prediction by Greisen and by Zatsepin and Kuz'min.
Collapse
Affiliation(s)
- J Abraham
- Universidad Tecnológica Nacional, FR-Mendoza, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Abraham J, Abreu P, Aglietta M, Aguirre C, Allard D, Allekotte I, Allen J, Allison P, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anzalone A, Aramo C, Argirò S, Arisaka K, Armengaud E, Arneodo F, Arqueros F, Asch T, Asorey H, Assis P, Atulugama BS, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Barbosa AF, Barnhill D, Barroso SLC, Bauleo P, Beatty JJ, Beau T, Becker BR, Becker KH, Bellido JA, BenZvi S, Berat C, Bergmann T, Bernardini P, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blasi P, Bleve C, Blümer H, Bohácová M, Bonifazi C, Bonino R, Boratav M, Brack J, Brogueira P, Brown WC, Buchholz P, Bueno A, Burton RE, Busca NG, Caballero-Mora KS, Cai B, Camin DV, Caramete L, Caruso R, Carvalho W, Castellina A, Catalano O, Cataldi G, Cazon L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chye J, Clark PDJ, Clay RW, Colombo E, Conceição R, Connolly B, Contreras F, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Criss A, Cronin J, Curutiu A, Dagoret-Campagne S, Daumiller K, Dawson BR, de Almeida RM, De Donato C, de Jong SJ, De La Vega G, de Mello Junior WJM, de Mello Neto JRT, DeMitri I, de Souza V, del Peral L, Deligny O, Della Selva A, Delle Fratte C, Dembinski H, Di Giulio C, Diaz JC, Dobrigkeit C, D'Olivo JC, Dornic D, Dorofeev A, dos Anjos JC, Dova MT, D'Urso D, Dutan I, DuVernois MA, Engel R, Epele L, Erdmann M, Escobar CO, Etchegoyen A, Facal San Luis P, Falcke H, Farrar G, Fauth AC, Fazzini N, Ferrer F, Ferry S, Fick B, Filevich A, Filipcic A, Fleck I, Fonte R, Fracchiolla CE, Fulgione W, García B, García Gámez D, Garcia-Pinto D, Garrido X, Geenen H, Gelmini G, Gemmeke H, Ghia PL, Giller M, Glass H, Gold MS, Golup G, Gomez Albarracin F, Gómez Berisso M, Gómez Herrero R, Gonçalves P, Gonçalves do Amaral M, Gonzalez D, Gonzalez JG, González M, Góra D, Gorgi A, Gouffon P, Grassi V, Grillo AF, Grunfeld C, Guardincerri Y, Guarino F, Guedes GP, Gutiérrez J, Hague JD, Hamilton JC, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hauschildt T, Healy MD, Hebbeker T, Hebrero G, Heck D, Hojvat C, Holmes VC, Homola P, Hörandel J, Horneffer A, Horvat M, Hrabovský M, Huege T, Hussain M, Iarlori M, Insolia A, Ionita F, Italiano A, Kaducak M, Kampert KH, Karova T, Kégl B, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Krieger A, Krömer O, Kuempel D, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lebrun D, Lebrun P, Lee J, Leigui de Oliveira MA, Letessier-Selvon A, Leuthold M, Lhenry-Yvon I, López R, Lopez Agüera A, Lozano Bahilo J, Luna García R, Maccarone MC, Macolino C, Maldera S, Mancarella G, Manceñido ME, Mandat D, Mantsch P, Mariazzi AG, Maris IC, Marquez Falcon HR, Martello D, Martínez J, Martínez Bravo O, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, McCauley T, McEwen M, McNeil RR, Medina MC, Medina-Tanco G, Meli A, Melo D, Menichetti E, Menschikov A, Meurer C, Meyhandan R, Micheletti MI, Miele G, Miller W, Mollerach S, Monasor M, Monnier Ragaigne D, Montanet F, Morales B, Morello C, Moreno JC, Morris C, Mostafá M, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Necesal P, Nellen L, Newman-Holmes C, Newton D, Nguyen Thi T, Nierstenhoefer N, Nitz D, Nosek D, Nozka L, Oehlschläger J, Ohnuki T, Olinto A, Olmos-Gilbaja VM, Ortiz M, Ortolani F, Ostapchenko S, Otero L, Pacheco N, Pakk Selmi-Dei D, Palatka M, Pallotta J, Parente G, Parizot E, Parlati S, Pastor S, Patel M, Paul T, Pavlidou V, Payet K, Pech M, Pekala J, Pelayo R, Pepe IM, Perrone L, Petrera S, Petrinca P, Petrov Y, Pham Ngoc D, Pham Ngoc D, Pham Thi TN, Pichel A, Piegaia R, Pierog T, Pimenta M, Pinto T, Pirronello V, Pisanti O, Platino M, Pochon J, Privitera P, Prouza M, Quel EJ, Rautenberg J, Redondo A, Reucroft S, Revenu B, Rezende FAS, Ridky J, Riggi S, Risse M, Rivière C, Rizi V, Roberts M, Robledo C, Rodriguez G, Rodríguez Frías D, Rodriguez Martino J, Rodriguez Rojo J, Rodriguez-Cabo I, Ros G, Rosado J, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos EM, Sarazin F, Sarkar S, Sato R, Scherini V, Schieler H, Schmidt A, Schmidt F, Schmidt T, Scholten O, Schovánek P, Schüssler F, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shellard RC, Sidelnik I, Siffert BB, Sigl G, Smetniansky De Grande N, Smiałkowski A, Smída R, Smith AGK, Smith BE, Snow GR, Sokolsky P, Sommers P, Sorokin J, Spinka H, Squartini R, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Takahashi J, Tamashiro A, Tamburro A, Taşcău O, Tcaciuc R, Thomas D, Ticona R, Tiffenberg J, Timmermans C, Tkaczyk W, Todero Peixoto CJ, Tomé B, Tonachini A, Torres I, Torresi D, Travnicek P, Tripathi A, Tristram G, Tscherniakhovski D, Tueros M, Tunnicliffe V, Ulrich R, Unger M, Urban M, Valdés Galicia JF, Valiño I, Valore L, van den Berg AM, van Elewyck V, Vázquez RA, Veberic D, Veiga A, Velarde A, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wainberg O, Walker P, Warner D, Watson AA, Westerhoff S, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Wileman C, Winnick MG, Wu H, Wundheiler B, Yamamoto T, Younk P, Zas E, Zavrtanik D, Zavrtanik M, Zech A, Zepeda A, Ziolkowski M. Upper limit on the diffuse flux of ultrahigh energy tau neutrinos from the Pierre Auger Observatory. Phys Rev Lett 2008; 100:211101. [PMID: 18518595 DOI: 10.1103/physrevlett.100.211101] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/11/2007] [Indexed: 05/26/2023]
Abstract
The surface detector array of the Pierre Auger Observatory is sensitive to Earth-skimming tau neutrinos that interact in Earth's crust. Tau leptons from nu(tau) charged-current interactions can emerge and decay in the atmosphere to produce a nearly horizontal shower with a significant electromagnetic component. The data collected between 1 January 2004 and 31 August 2007 are used to place an upper limit on the diffuse flux of nu(tau) at EeV energies. Assuming an E(nu)(-2) differential energy spectrum the limit set at 90% C.L. is E(nu)(2)dN(nu)(tau)/dE(nu)<1.3 x 10(-7) GeV cm(-2) s(-1) sr(-1) in the energy range 2 x 10(17) eV< E(nu)< 2 x 10(19) eV.
Collapse
Affiliation(s)
- J Abraham
- Centro de Investigaciones en Laseres y Aplicaciones, CITEFA and CONICET, Argentina
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
93
|
Pignochino Y, Grignani G, Cavalloni G, Motta M, Bruno S, Camussi G, Ferrari S, Picci P, Berger M, Aglietta M. Antitumor activity of sorafenib in osteosarcoma (OS) preclinical models. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
94
|
Aliberti S, Allione P, Grignani G, Carnevale Schianca F, Fizzotti M, Rota Scalabrini D, Caravelli D, Russo F, Debernardi S, Aglietta M. Use of FDG-PET (PET) to select patients for metastasectomy for high-grade soft tissue sarcomas (HG-STS). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
95
|
Pedrazzoli P, Gianni AM, Da Prada G, Ballestrero A, Martino MV, Rosti G, Bregni M, Aglietta M, Bengala C, Martinelli G. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for breast cancer with > 9 positive nodes: 15-year results from the Italian registry. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.592] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
96
|
Abraham J, Abreu P, Aglietta M, Aguirre C, Allard D, Allekotte I, Allen J, Allison P, Alvarez C, Alvarez-Muñiz J, Ambrosio M, Anchordoqui L, Andringa S, Anzalone A, Aramo C, Argirò S, Arisaka K, Armengaud E, Arneodo F, Arqueros F, Asch T, Asorey H, Assis P, Atulugama BS, Aublin J, Ave M, Avila G, Bäcker T, Badagnani D, Barbosa AF, Barnhill D, Barroso SLC, Bauleo P, Beatty J, Beau T, Becker BR, Becker KH, Bellido JA, BenZvi S, Berat C, Bergmann T, Bernardini P, Bertou X, Biermann PL, Billoir P, Blanch-Bigas O, Blanco F, Blasi P, Bleve C, Blümer H, Boháčová M, Bonifazi C, Bonino R, Boratav M, Brack J, Brogueira P, Brown WC, Buchholz P, Bueno A, Busca NG, Caballero-Mora KS, Cai B, Camin DV, Caruso R, Carvalho W, Castellina A, Catalano O, Cataldi G, Cazón-Boado L, Cester R, Chauvin J, Chiavassa A, Chinellato JA, Chou A, Chye J, Clark PDJ, Clay RW, Colombo E, Conceição R, Connolly B, Contreras F, Coppens J, Cordier A, Cotti U, Coutu S, Covault CE, Creusot A, Cronin J, Dagoret-Campagne S, Daumiller K, Dawson BR, de Almeida RM, De Donato C, de Jong SJ, De La Vega G, de Mello Junior WJM, de Mello Neto JRT, De Mitri I, de Souza V, del Peral L, Deligny O, Selva AD, Fratte CD, Dembinski H, Di Giulio C, Diaz JC, Dobrigkeit C, D'Olivo JC, Dornic D, Dorofeev A, Anjos JCD, Dova MT, D'Urso D, DuVernois MA, Engel R, Epele L, Erdmann M, Escobar CO, Etchegoyen A, Luis PFS, Falcke H, Farrar G, Fauth AC, Fazzini N, Fernández A, Ferrer F, Ferry S, Fick B, Filevich A, Filipčič A, Fleck I, Fonte R, Fracchiolla CE, Fulgione W, García B, García Gámez D, Garcia-Pinto D, Garrido X, Geenen H, Gelmini G, Gemmeke H, Ghia PL, Giller M, Glass H, Gold MS, Golup G, Albarracin FG, Berisso MG, Herrero RG, Gonçalves P, do Amaral MG, Gonzalez D, Gonzalez JG, González M, Góra D, Gorgi A, Gouffon P, Grassi V, Grillo A, Grunfeld C, Guardincerri Y, Guarino F, Guedes GP, Gutiérrez J, Hague JD, Hamilton JC, Hansen P, Harari D, Harmsma S, Harton JL, Haungs A, Hauschildt T, Healy MD, Hebbeker T, Heck D, Hojvat C, Holmes VC, Homola P, Hörandel J, Horneffer A, Horvat M, Hrabovský M, Huege T, Iarlori M, Insolia A, Ionita F, Italiano A, Kaducak M, Kampert KH, Keilhauer B, Kemp E, Kieckhafer RM, Klages HO, Kleifges M, Kleinfeller J, Knapik R, Knapp J, Koang DH, Kopmann A, Krieger A, Krömer O, Kümpel D, Kunka N, Kusenko A, La Rosa G, Lachaud C, Lago BL, Lebrun D, LeBrun P, Lee J, de Oliveira MAL, Letessier-Selvon A, Leuthold M, Lhenry-Yvon I, López R, Lopez Agüera A, Bahilo JL, Maccarone MC, Macolino C, Maldera S, Malek M, Mancarella G, Manceñido ME, Mandat D, Mantsch P, Mariazzi AG, Maris IC, Martello D, Martínez J, Bravo OM, Mathes HJ, Matthews J, Matthews JAJ, Matthiae G, Maurizio D, Mazur PO, McCauley T, McEwen M, McNeil RR, Medina MC, Medina-Tanco G, Meli A, Melo D, Menichetti E, Menschikov A, Meurer C, Meyhandan R, Micheletti MI, Miele G, Miller W, Mollerach S, Monasor M, Ragaigne DM, Montanet F, Morales B, Morello C, Moreno E, Moreno JC, Morris C, Mostafá M, Muller MA, Mussa R, Navarra G, Navarro JL, Navas S, Nellen L, Newman-Holmes C, Newton D, Thi TN, Nierstenhöfer N, Nitz D, Nosek D, Nožka L, Oehlschläger J, Ohnuki T, Olinto A, Olmos-Gilbaja VM, Ortiz M, Ostapchenko S, Otero L, Selmi-Dei DP, Palatka M, Pallotta J, Parente G, Parizot E, Parlati S, Pastor S, Patel M, Paul T, Pavlidou V, Payet K, Pech M, Pȩkala J, Pelayo R, Pepe IM, Perrone L, Petrera S, Petrinca P, Petrov Y, Ngoc D, Ngoc D, Thi TNP, Pichel A, Piegaia R, Pierog T, Pimenta M, Pinto T, Pirronello V, Pisanti O, Platino M, Pochon J, Porter TA, Privitera P, Prouza M, Quel EJ, Rautenberg J, Reucroft S, Revenu B, Rezende FAS, Řídký J, Riggi S, Risse M, Rivière C, Rizi V, Roberts M, Robledo C, Rodriguez G, Frías DR, Martino JR, Rojo JR, Rodriguez-Cabo I, Ros G, Rosado J, Roth M, Rouillé-d'Orfeuil B, Roulet E, Rovero AC, Salamida F, Salazar H, Salina G, Sánchez F, Santander M, Santo CE, Santos EM, Sarazin F, Sarkar S, Sato R, Scherini V, Schieler H, Schmidt F, Schmidt T, Scholten O, Schovánek P, Schüssler F, Sciutto SJ, Scuderi M, Segreto A, Semikoz D, Settimo M, Shellard RC, Sidelnik I, Siffert BB, Sigl G, De Grande NS, Smiałkowski A, šmída R, Smith AGK, Smith BE, Snow GR, Sokolsky P, Sommers P, Sorokin J, Spinka H, Squartini R, Strazzeri E, Stutz A, Suarez F, Suomijärvi T, Supanitsky AD, Sutherland MS, Swain J, Szadkowski Z, Takahashi J, Tamashiro A, Tamburro A, Taşcău O, Tcaciuc R, Thomas D, Ticona R, Tiffenberg J, Timmermans C, Tkaczyk W, Peixoto CJT, Tomé B, Tonachini A, Torresi D, Travnicek P, Tripathi A, Tristram G, Tscherniakhovski D, Tueros M, Tunnicliffe V, Ulrich R, Unger M, Urban M, Galicia JFV, Valiño I, Valore L, van den Berg AM, van Elewyck V, Vázquez RA, Veberič D, Veiga A, Velarde A, Venters T, Verzi V, Videla M, Villaseñor L, Vorobiov S, Voyvodic L, Wahlberg H, Wainberg O, Waldenmaier T, Walker P, Warner D, Watson AA, Westerhoff S, Wieczorek G, Wiencke L, Wilczyńska B, Wilczyński H, Wileman C, Winnick MG, Wu H, Wundheiler B, Xu J, Yamamoto T, Younk P, Zas E, Zavrtanik D, Zavrtanik M, Zech A, Zepeda A, Ziolkowski M. Correlation of the Highest-Energy Cosmic Rays with Nearby Extragalactic Objects. Science 2007; 318:938-43. [DOI: 10.1126/science.1151124] [Citation(s) in RCA: 560] [Impact Index Per Article: 32.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
97
|
Sapino A, Montemurro F, Marchiò C, Viale G, Kulka J, Donadio M, Bottini A, Botti G, dei Tos AP, Bersiga A, Di Palma S, Truini M, Sanna G, Aglietta M, Bussolati G. Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann Oncol 2007; 18:1963-8. [PMID: 17785760 DOI: 10.1093/annonc/mdm417] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Biotin-labeled trastuzumab (BiotHER) can be used to test for HER2 by immunohistochemistry. We previously showed that BiotHER immunoreactivity is highly correlated with HER2 amplification and indicated that it could be associated with better clinical outcome in advanced breast cancer patients receiving trastuzumab. PATIENTS AND METHODS Tumor specimens and clinical information from 234 patients who received trastuzumab-based treatments were collected from 10 institutions. HER2 amplification and BiotHER immunoreactivity were assessed centrally. The effect of BiotHER positivity on response rate (RR), time to progression and survival were studied by univariate and multivariate analysis in patients presenting HER2-amplified breast cancer. The pathologic reviews of the assays were blinded to patient outcomes. RESULTS BiotHER was positive in 109/194 (56%) HER2-amplified breast cancers and in one not amplified tumor. RRs were 74% [95% (confidence interval) CI 64%-81%] and 47% (95% CI 36%-58%) in BiotHER-positive and -negative tumors, respectively (P < 0.001). BiotHER immunoreactivity was independently associated with increased probability of tumor response (odds ratio 3.848; 95% CI 1.952-7.582), with reduced risk of disease progression [hazard ratio (HR) 0.438; 95% CI 0.303-0.633] and with reduced risk of death (HR 0.566; 95% CI 0.368-0.870) by multivariate analysis. CONCLUSION The results support a role for BiotHER testing in better tailoring trastuzumab-based treatments in patients with advanced HER2-amplified breast cancers.
Collapse
Affiliation(s)
- A Sapino
- Dipartimento di Scienze Biomediche e Oncologia Umana, Università di Torino, Torino, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
98
|
Fusco V, Aglietta M, Donadio M, Berruti A, Baraldi A, Ortega C, Vandone A, Galassi C, Bertetto O. 1131 POSTER Osteonecrosis of the jaw (ONJ) in patients treated with Bisphosphonates (BP): the experience of the "Rete Oncologica di Piemonte e Valle D'Aosta" (North-Western Italy). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70650-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
99
|
Aglietta M, Pignochino Y, Cavalloni G, Sarotto I, Penachioni J, Zanon C, Migliardi G, Piacibello W, Risio M, Bardelli A, Leone F. Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4582 Background: Biliary tract carcinomas express EGFR and are potential candidates to EGFR target therapies. We recently described somatic mutations of EGFR that can enhance MAPK or Akt activation (Clin Cancer Res, 2006). Some of them are identical to those previously reported to confer sensitivity to some tyrosine kinase inhibitors (TKIs) like erlotinib or gefitinib in lung cancer. Here we report a molecular analysis of EGFR transducers potentially involved in TKI response. Methods: In 49 samples of biliary tract carcinoma we performed mutational analysis of exons from 18 to 21 of EGFR, exons 9 and 20 of phosphatidylinositol 3’-kinase (PI3K), exon 2 of K-Ras, exon 15 of B-Raf and exons from 5 to 8 of PTEN. Nuclear PTEN expression was analyzed by immunohistochemistry and the expression in cancer cells was compared to that of normal cholangiocites. Results: Mutations of EGFR have been detected in 7 out of 49 samples (14.3%). One of them was a new stop-codon mutation. Five hotspot mutations of PI3K (codon 545, 546, 1048 and 1059) were found in 4 cases (8.2%); 3 cases (6.1%) had single mutations in K-Ras and 4 (8.2%) had the V599E mutation in B-Raf. In some samples, mutations of multiple trasducers were present simultaneously. PI3K mutations were significantly more frequent in EGFR mutated samples compared to wild type (28% vs. 4.7% respectively, p<0.05). A single F271L mutation of PTEN was observed (2%). We did not find loss of nuclear PTEN in biliary tract carcinoma cells; rather, a stronger labelling intensity (score 2+ or 3+) was present in biliary tract carcinoma compared to normal cholangiocites (score 1+). Moreover, the median percentage of PTEN labeled nuclei in tumor cells was 31.8%, but in samples with activating EGFR mutation was 60%, suggesting that a compensatory change in the level of the phosphatase might counteract the EGFR activition. Conclusions: These results corroborate our previous finding of EGFR pathway activation in EGFR mutated biliary tract carcinoma and suggest that an accurate analysis of the entire series of EGFR transducers may be done before planning treatments with TKIs. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Aglietta
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - Y. Pignochino
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - G. Cavalloni
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - I. Sarotto
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - J. Penachioni
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - C. Zanon
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - G. Migliardi
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - W. Piacibello
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - M. Risio
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - A. Bardelli
- Institute of Cancer Research and Treatment, Candiolo, Italy
| | - F. Leone
- Institute of Cancer Research and Treatment, Candiolo, Italy
| |
Collapse
|
100
|
Vormola R, Ortega C, Montemurro F, Capaldi A, Cirillo S, Gabriele P, Muto G, Aglietta M. Correlation of 11C-choline PET and PSA values in patients with prostate cancer and biochemical relapse after primary treatments. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5073] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5073 Background: 11C-choline PET has demonstrated promising results in the evaluation of suspected recurrence after a primary treatment in prostate cancer (PC) patients (pts). However in pts with asymptomatic biochemical relapse (BR), the timing of PET scan is a subject of controversy. Most authors argue against performing PET scan for rising PSA values <5 ng/ml. Aim of our study was to evaluate if there is a PSA cut-off that significatively correlates to 11C-choline PET positivity. Methods: 68 pts with rising PSA after primary treatment underwent 11C-choline PET. Median age was 68 yrs (range 43–84). Median PSA at the time of PET scan was 2.91 ng/ml (range 0.12- 71.60). Primary treatments were: 27 (40%) radical prostatectomy (RP), 22 (32%) external-beam radiation therapy (EBRT), 13 (19%) RP + adjuvant EBRT, 6 (9%) hormonal therapy. Results: 11C-choline PET was positive in 39/68 pts (57%) and negative in 29/68 (43%). Median PSA values were 1.18 ng/ml (range 0.12–6.47) and 5.14 ng/ml (range 1.33–71.60) in pts with negative and positive PET scan respectively. Median PSA values were statistically different in positive and negative 11C-choline PET (Mann-Whitney U Test. p< 0.001). No positive uptake was seen in pts with PSA <1 ng/ml (12/68); all pts with PSA >6.5 ng/ml had a positive finding; for PSA values between 1 and 6.5 ng/ml (33/68), 11C- choline PET showed a pathological uptake in 18 pts. The Receiver Operative Characteristic (ROC) analysis found that a PSA cut-off of 2.31 ng/ml has a sensitivity of 87% and a specificity of 83% in respect of 11C-choline PET positivity. Conclusions: For PSA values > 2.3 ng/ml the probability to have a positive 11C-choline PET is high in order to recommend to perform the exam in clinical practice, even if further data are needed. On the contrary, we can’t suggest to perform PET scan in pts with PSA <1 ng/ml. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Vormola
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - C. Ortega
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - F. Montemurro
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - A. Capaldi
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - S. Cirillo
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - P. Gabriele
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - G. Muto
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| | - M. Aglietta
- Institute for Cancer Research and Treatment, Candiolo (TO), Italy; S Giovanni Bosco Hospital, Torino, Italy
| |
Collapse
|